Enanta Pharmaceuticals to Appeal Ruling Related to ‘953 Patent Infringement Lawsuit

ENTA 12.24.2024

Full Press ReleaseSEC FilingsOur ENTA Tweets

About Gravity Analytica

Recent News

  • 01.15.2025 - 43rd Annual J.P. Morgan Healthcare Conference
  • 01.08.2025 - Enanta Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
  • 12.24.2024 - Enanta Pharmaceuticals to Appeal Ruling Related to ‘953 Patent Infringement Lawsuit

Recent Filings

  • 01.22.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
  • 12.10.2024 - 4 Statement of changes in beneficial ownership of securities
  • 12.09.2024 - EX-99.1 EX-99.1
PDF Version

WATERTOWN, Mass.--(BUSINESS WIRE)--Dec. 24, 2024--Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that theUnited States District Court of Massachusetts(“the Court”) has issued a ruling on a summary judgment motion filed byPfizer, Inc.in connection with Enanta’s patent infringement lawsuit seeking damages for infringement ofU.S.Patent No. 11,358,953 (“the ’953 Patent”) in the manufacture, use and sale of Pfizer’s COVID-19 antiviral, PaxlovidTM (nirmatrelvir tablets; ritonavir tablets).

The Court issued a summary judgment decision granting Pfizer’s motion that the ‘953 Patent is invalid. In its decision, the Court also denied Enanta’s partial motion for summary judgment of infringement as moot in light of its allowance of summary judgment on invalidity. Enanta plans to appeal the decision to theCourt of Appeals for the Federal Circuit.

"TheU.S.patent system and its protection of important innovations have enabled the robust development of new medicines and spurred growth in the biotechnology industry. We are proud of the impact our strong history of drug discovery work with protease inhibitors has had on antiviral treatments and the thousands of patients that have been treated with therapies using our patented inventions,” saidJay R. Luly, Ph.D., President and Chief Executive Officer ofEnanta Pharmaceuticals, Inc.“We are disappointed with the Court’s ruling. We believe strongly in the merits of our case, and, through the appeal process, we will continue to defend our inventions from unlawful infringement.”

Enanta maintains its commitment to avoid attempting to impede the production, sale or distribution of Paxlovid.

AboutEnanta Pharmaceuticals, Inc.

Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs with an emphasis on indications in virology and immunology. Enanta’s clinical programs are currently focused on respiratory syncytial virus (RSV) and its earlier-stage immunology pipeline aims to develop treatments for inflammatory diseases by targeting key drivers of the type 2 immune response, including KIT and STAT6 inhibition.

Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing chronic hepatitis c virus (HCV) infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET® (U.S.) and MAVIRET® (ex-U.S.) (glecaprevir/pibrentasvir). A portion of Enanta’s royalties from HCV products developed under its collaboration with AbbVie contribute ongoing funding to Enanta’s operations. Please visitwww.enanta.comfor more information.

Forward-Looking Statements

This press release contains forward-looking statements, including statements with respect to Enanta’s suit againstPfizer, Inc.in theUnited States District Court for the District of Massachusettsseeking damages for patent infringement. Statements that are not historical facts are based on management’s current expectations, estimates, forecasts and projections about Enanta’s business and the industry in which it operates and management’s beliefs and assumptions. The statements contained in this release are not guarantees of future performance and involve certain risks, uncertainties and assumptions, which are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed in such forward-looking statements. Important factors and risks that may affect actual results include: Enanta is competing to develop intellectual property in areas of small-molecule drug development that are highly competitive; issued patents, including the patent at issue in the Pfizer litigation, could be found invalid or unenforceable if challenged in court and could be costly to defend and be a distraction for Enanta’s senior management and scientific personnel; intellectual property litigation may lead to unfavorable publicity that harms Enanta’s reputation and causes the market price of its common stock to decline; and other risk factors described or referred to in “Risk Factors” in Enanta’s Form 10-K for the fiscal year endedSeptember 30, 2024and other periodic reports filed more recently with theSecurities and Exchange Commission. Enanta cautions investors not to place undue reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this release, and Enanta undertakes no obligation to update or revise these statements, except as may be required by law.

View source version onbusinesswire.com:https://www.businesswire.com/news/home/20241224565771/en/

Media and Investors:Jennifer Viera617-744-3848jviera@enanta.com

Source:Enanta Pharmaceuticals, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com